FinOracle AI’s Post

I'm continually impressed by the incredible progress of VK2809, by Viking Therapeutics, Inc.. As they continue to innovate, a purpose-driven brand strategy can amplify their impact even further. Let's connect to explore how we can elevate this remarkable product to new heights! #Pharma #Biotech #MedDevice #BrandStrategy #PurposeDriven #AmplifyYourVoice #NASH #AddisonWhitney

Today, Biotage published its Q1 results. We delivered very good results for the first quarter with stronger gross margins and adjusted EBITDA. Our new strategy that focuses on being the Global Go-To Separation company, with a well-balanced product portfolio is paying dividends. Our Biologics and Advanced Therapeutics segment accounted for 30% of total revenue during the quarter. We believe this segment will continue to show attractive growth over the next few years. Our commitment to increase the recurring revenue streams, a central element of our strategy, is evident in its ascent to 72% of our total business, up from 59% in Q1 2023. More information on the results https://hubs.ly/Q02v034X0 #biotage #quarterlyresults #lifescience

Biotage 2024 Q results are out! See how the Global Go-To Separation company did at the begining of this year! Check out how our Biologics and Advanced Therapeutics functions are performing (hint its over 30% of total revenue for the quater)! Leading by Example and delivering for the customer as well as shareholders! Dont take my word for it, check out the report! #Biotage #GoToSeparationsCompany #LargeAndSmallMolecules #BeTheBest

Thoughts on this? >> Lyell Immunopharma to acquire ImmPACT Bio, cut top programs >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #biotech #pharmaceutical #healthcare #productmarketing

📈🧬📉 Biotech & Pharma Stock Market Recap May 20 - 24, 2024 Covering the Winners & Losers of the week, and a look at the earnings calls coming up next week. This weekend edition is a new feature at TLDR Biotech, so I’d love to get your feedback. Link to the recap in the comments! #biotech #pharma #biotechnews #pharmanews #tldrbiotech

After the worst downturn in biotech history, are there finally signs of optimism heading into the second half? Join BioCentury Inc. and Oppenheimer & Co. Inc. for an in-depth discussion with investors and pharma dealmakers about where the biotech market is headed.   Register for this complimentary webinar to join live and ask questions, or watch the recorded version at your convenience: https://lnkd.in/gkZBPBaq Moderator: Stephen Hansen, BioCentury Inc. Panelists: Ario Arabi, Novartis Nina Kjellson, Canaan Partners Andrew W. Lam, PharmD, Ally Bridge Group Michael Margolis, Oppenheimer & Co. Inc. Nimish Shah, Venrock #biotech #biopharma #pharma #investors #dealmakers #capitalmarkets #VCs #capitalmarketspreview

Thoughts on this? >> Lyell Immunopharma to acquire ImmPACT Bio, cut top programs >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharma #biotech #healthcare #pharmaceutical

First edition of the weekend biotech & pharma stock review at TLDR Biotech! If you get a chance to read it, please let me know what you think. #biotech #biotechnews #pharma #pharmanews #tldrbiotech

Biotage’s 2023 Annual Report is out now bringing together last year’s key activities and highlights. ✔ Astrea Bioseparations, a high-growth biological chromatography solutions provider, became part of Biotage. This strategic acquisition marks a significant expansion for Biotage into the thriving bioprocessing sector.   ✔ The share of Biologics and Advanced Therapeutics product area went up to 24% of our total revenue in 2023.   ✔ Our commitment to advancing our customers’ peptide and flash purification workflows resulted in the launch of several solutions to drive efficiency and improved outcomes.   ✔ In alignment with the new European Standards and Directives, we have performed a double materiality analysis that looks at our sustainability impact long and short term.   Explore more insights in the full report at https://lnkd.in/gqwGWCdE #biotage #annualreport2023 #pharma #biopharma

Today Biotage shared its Q4 and full year 2023 results. We had a strong finish to the year, propelled by the exceptional performance of Astrea Bioseparations. Revenue, gross margins, cash generation and profitability all showed good growth in Q4, capping a successful 2023. Biologics and Advanced Therapeutics now account for nearly 25% of our full year revenue compared to just 4% in 2022. Additionally, our focus on recurring revenue streams, including consumables and services, has paid off, representing 76% of Q4 revenue and 67% for the full year. 2023 was a transformative year for Biotage. We have achieved a better-balanced business and are directing our efforts towards faster-growing segments. We look forward to the future with excitement and optimism. More information on the results https://hubs.ly/Q02l9v6h0 #biotage #quarterlyresults #lifescience